Citations

Clear

2286 citation(s) found for "Yu, Anthony".

Artificial Intelligence-Enabled ECG Algorithm to Identify Patients With Left Ventricular Systolic Dysfunction Presenting to the Emergency Department With Dyspnea
Adedinsewo, Demilade , Carter, Rickey E. , Attia, Zachi I. , Kashou, Anthony H. , Dugan, Jennifer , Albus, Michael, Bellolio, Fernanda , Friedman, Paul A. , Johnson, Patrick, Dugan, Jennifer L, Sheele, Johnathan M. , Carter, Rickey E , Adedinsewo, Demilade A , Bellolio, M Fernanda , Attia, Zachi I , Johnson, Patrick W. , López-Jiménez, Francisco , Noseworthy, Peter A.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | August 4, 2020 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/circep.120.008437 | PMID 32986471 Get It

Background: Identification of systolic heart failure among patients presenting to the emergency department (ED) with acute dyspnea is challenging. The reasons for dyspnea are often multifactorial. A focused physical evaluation and diagnostic testing can lack sensitivity and specificity. The objective of this study was to assess the accuracy of an artificial intelligence-enabled ECG to identify patients presenting with dyspnea who have left ventricular systolic dysfunction (LVSD). Methods: We retrospectively applied a validated artificial intelligence-enabled ECG algorithm for the identification of LVSD (defined as LV ejection fraction ≤35%) to a cohort of patients aged ≥18 years who were evaluated in the ED at a Mayo Clinic site with dyspnea. Patients were included if they had at least one standard 12-lead ECG acquired on the date of the ED visit and an echocardiogram performed within 30 days of presentation. Patients with prior LVSD were excluded. We assessed the model performance using area under the receiver operating characteristic curve, accuracy, sensitivity, and specificity. Results: A total of 1606 patients were included. Median time from ECG to echocardiogram was 1 day (Q1: 1, Q3: 2). The artificial intelligence-enabled ECG algorithm identified LVSD with an area under the receiver operating characteristic curve of 0.89 (95% CI, 0.86–0.91) and accuracy of 85.9%. Sensitivity, specificity, negative predictive value, and positive predictive value were 74%, 87%, 97%, and 40%, respectively. To identify an ejection fraction <50%, the area under the receiver operating characteristic curve, accuracy, sensitivity, and specificity were 0.85 (95% CI, 0.83–0.88), 86%, 63%, and 91%, respectively. NT-proBNP (N-terminal pro-B-type natriuretic peptide) alone at a cutoff of >800 identified LVSD with an area under the receiver operating characteristic curve of 0.80 (95% CI, 0.76–0.84). Conclusions: The ECG is an inexpensive, ubiquitous, painless test which can be quickly obtained in the ED. It effectively identifies LVSD in selected patients presenting to the ED with dyspnea when analyzed with artificial intelligence and outperforms NT-proBNP. Graphic Abstract: A graphic abstract is available for this article.
Regional improvements in lumbosacropelvic Hounsfield units following teriparatide treatment
Mikula, Anthony L. , Peters, Pierce A., Oushy, Soliman , Fogelson, Jeremy L. , Bydon, Mohamad , Freedman, Brett A. , Sebastian, Arjun S. , Currier, Bradford L. , Kennel, Kurt A. , Anderson, Paul A. , Polly, David W. , Elder, Benjamin D. , Oushy, Soliman H , Flanigan, Patrick Michael , Nassr, Ahmad , Polly, David

Mayo Clinic

Neurosurgical Focus | August 1, 2020 | Volume: 49 | Issue: 2 | Pages: E11

10.3171/2020.5.focus20273 | PMID 32738792 Get It

OBJECTIVE Opportunistic Hounsfield unit (HU) determination from CT imaging has been increasingly used to estimate bone mineral density (BMD) in conjunction with assessments from dual energy x-ray absorptiometry (DXA). The authors sought to compare the effect of teriparatide on HUs across different regions in the pelvis, sacrum, and lumbar spine, as a surrogate measure for the effects of teriparatide on lumbosacropelvic instrumentation. METHODS A single-institution retrospective review of patients who had been treated with at least 6 months of teriparatide was performed. All patients had at least baseline DXA as well as pre- and post-teriparatide CT imaging. HUs were measured in the pedicle, lamina, and vertebral body of the lumbar spine, in the sciatic notch, and at the S1 and S2 levels at three different points (ilium, sacral body, and sacral ala). RESULTS Forty patients with an average age of 67 years underwent a mean of 20 months of teriparatide therapy. Mean HUs of the lumbar lamina, pedicles, and vertebral body were significantly different from each other before teriparatide treatment: 343 ± 114, 219 ± 89.2, and 111 ± 48.1, respectively (p < 0.001). Mean HUs at the S1 level for the ilium, sacral ala, and sacral body were also significantly different from each other: 124 ± 90.1, −10.7 ± 61.9, and 99.1 ± 72.1, respectively (p < 0.001). The mean HUs at the S2 level for the ilium and sacral body were not significantly different from each other, although the mean HU at the sacral ala (−11.9 ± 52.6) was significantly lower than those at the ilium and sacral body (p = 0.003 and 0.006, respectively). HU improvement occurred in most regions following teriparatide treatment. In the lumbar spine, the mean lamina HU increased from 343 to 400 (p < 0.001), the mean pedicle HU increased from 219 to 242 (p = 0.04), and the mean vertebral body HU increased from 111 to 134 (p < 0.001). There were also significant increases in the S1 sacral body (99.1 to 130, p < 0.05), S1 ilium (124 vs 165, p = 0.01), S1 sacral ala (−10.7 vs 3.68, p = 0.04), and S2 sacral body (168 vs 189, p < 0.05). CONCLUSIONS There was significant regional variation in lumbar and sacropelvic HUs, with most regions significantly increasing following teriparatide treatment. The sacropelvic area had lower HU values than the lumbar spine, more regional variation, and a higher degree of correlation with BMD as measured on DXA. While teriparatide treatment resulted in HUs > 110 in the majority of the lumbosacral spine, the HUs in the sacral ala remained suggestive of severe osteoporosis, which may limit the effectiveness of fixation in this region.
Three‐dimensional printing facilitates surgical planning for resection of an atypical cardiac myxoma
Ali, Mojahid, Pham, Anthony , Pooley, Robert A. , Rojas, Carlos A. , Mergo, Patricia J. , Pham, Si M. , Pham, Anthony N , Pham, Si

Mayo Clinic

Journal of Cardiac Surgery | July 28, 2020 | Volume: 35 | Issue: 10 | Pages: 2863-2865

10.1111/jocs.14896 | PMID 32720392 Get It

Aß 40 Mutants Protect Drosophila Against aß 42 Toxicity Despite Their Amyloidogenic Properties in the Non-transgenic Mouse Brain
Smith, M. Hamblin, Dunton, Katie L, Ceballos‐Diaz, Carolina, Jansen‐West, Karen , Dillon, Kristy, Golde, Todd E. , Levites, Yona , Mena, Lorena de , Smith, Michael, Martin, Jason Anthony , Cruz, Pedro E. , Rincón-Limas, Diego E. , Moore, Brenda D.

Mayo Clinic

No container title available | July 27, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-47473/v1 Get It

Abstract BackgroundSelf-assembly of the amyloid-β (Aβ) peptide into aggregates, ranging from small oligomers to amyloid fibrils, is fundamentally linked with Alzheimer’s disease (AD). However it is clear that not all forms of Aβ are equally harmful, and that linking a specific aggregate to toxicity also depends on the assays and model systems used [1, 2]. Indeed, though a central postulate of the amyloid cascade hypothesis, there remain many gaps in our understanding regarding the links between Aβ deposition and neurodegeneration.MethodsIn this study we utilized BRI2-Aβ fusion technology and rAAV2/1 based somatic brain transgenesis to examine Aβ aggregates that form from selective expression of individual mutant Aβ species in vivo. In parallel we generated PhiC31-based transgenic Drosophila melanogaster expressing WT and mutant Aβ40 and Aβ42, fused to the Argos signal peptide and placed under the GAL4-upstream activation sequence (UAS) expression system in order to assess the extent of Aβ42-induced toxicity as well as to interrogate the combined effect of different forms of Aβ40 and Aβ42 species.ResultsWhen expressed in the mouse brain for 6 months, Aβ42 E22G, Aβ42 E22Q/D23N, and Aβ42 WT formed amyloid aggregates consisting of some diffuse material as well as cored plaques, whereas other mutants formed predominantly diffuse amyloid deposits. Moreover, while Aβ40WT showed no distinctive phenotype, Aβ40 E22G and E22Q/D23N formed unique aggregates that accumulated in mouse brains. This is the first evidence that mutant Aβ40 overexpression leads to deposition under certain conditions. Interestingly, we found that mutant Aβ42 E22G, E22Q, and S26C, but not Aβ40, were toxic to the eye of the flies and exacerbated their behavior. In contrast, flies expressing a copy of Aβ40 (wild type [WT] or mutants) in addition to Aβ42 WT, showed improved phenotypes, suggesting possible protective qualities for Aβ40.ConclusionsThese studies suggest that some Aβ40 mutants form unique amyloid aggregates in mouse brains, despite being protective against Aβ42 toxicity in Drosophila, which highlights the significance of using different systems for a better understanding of AD pathogenicity and more accurate screening for new potential therapies.
Microglial calcium signaling is attuned to neuronal activity in awake mice
Umpierre, Anthony D. , Bystrom, Lauren , Ying, Yanlu , Wu, Long‐Jun , Bystrom, Lauren L, Liu, Yong U, Wu, Long-Jun , Umpierre, Anthony D , Liu, Yong , Worrell, Gregory A.

Mayo Clinic

eLife | July 27, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.56502 | PMID 32716294 Get It

Microglial calcium signaling underlies a number of key physiological and pathological processes in situ, but has not been studied in vivo in awake mice. Using multiple GCaMP6 variants targeted to microglia, we assessed how microglial calcium signaling responds to alterations in neuronal activity across a wide range. We find that only a small subset of microglial somata and processes exhibited spontaneous calcium transients in a chronic window preparation. However, hyperactive shifts in neuronal activity (kainate status epilepticus and CaMKIIa Gq DREADD activation) triggered increased microglial process calcium signaling, often concomitant with process extension. Additionally, hypoactive shifts in neuronal activity (isoflurane anesthesia and CaMKIIa Gi DREADD activation) also increased microglial process calcium signaling. Under hypoactive neuronal conditions, microglia also exhibited process extension and outgrowth with greater calcium signaling. Our work reveals that microglia have highly distinct microdomain signaling, and that processes specifically respond to bi-directional shifts in neuronal activity through increased calcium signaling.
Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry
Sharman, Jeff P. , Cocks, Kim , Nabhan, Chadi , Lamanna, Nicole , Grinblatt, David L. , Flowers, Christopher R. , Kiselev, Pavel , Swern, Arlene S., Sullivan, Kristen , Gharibo, Mecide, Flick, E. Dawn, Trigg, Andrew , Mato, Anthony R. , Kay, Neil E. , Davids, Matthew S.

Mayo Clinic

eJHaem | July 26, 2020 | Volume: 1 | Issue: 1 | Pages: 188-198

10.1002/jha2.67 | PMID 35847738 Get It

AbstractHealth‐related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) is important in guiding treatment decisions. However, the impact of CLL treatment initiation on HRQoL is unclear. We assessed HRQoL using the FACT‐Leu and EQ‐5D‐3L questionnaires in the Connect® CLL Registry, a large, US‐based, multicenter, prospective observational study of CLL patients enrolled between 2010 and 2014, prior to the introduction of novel therapies. Among 889 patients initiating first‐line therapy with chemoimmunotherapy or rituximab monotherapy, questionnaire completion rates were 95.7% and 95.8% at enrollment, and 70.8% and 69.4% at 12 months, for FACT‐Leu Total and EQ‐5D‐3L, respectively. For 849 patients completing all five FACT‐Leu components, average total scores were 135.7 at enrollment and 141.6 at 12 months. Among 526 patients with FACT‐Leu Total scores at enrollment and 12 months, clinically meaningful (≥11‐point) improvements or reductions were observed in 179 (34.0%) and 88 (16.7%) patients, respectively. Mean EQ‐5D‐3L index scores were 0.87 at enrollment and 12 months. Among 513 patients completing EQ‐5D‐3L at enrollment and 12 months, clinically meaningful (≥0.06‐point) improvements or reductions were observed in 125 (24.4%) and 116 (22.6%) patients, respectively. In the Connect® CLL Registry, HRQoL remained stable or slightly improved after 12 months of follow‐up.
Ethics and informatics in the age of COVID-19: challenges and recommendations for public health organization and public policy
Subbian, Vignesh , Clarkson, Melissa D. , Rahimzadeh, Vasiliki , Petersen, Carolyn , Schreiber, Richard , DeMuro, Paul R. , Dua, Prerna, Goodman, Kenneth W. , Kaplan, Bonnie J. , Lehmann, Christoph U. , Pan, Eric, Goodman, Kenneth W , Lehmann, Christoph U , Petersen, Carolyn , Subbian, Vignesh , Solomonides, Anthony , Kaplan, Bonnie, Koppel, Ross , Senathirajah, Yalini

Mayo Clinic

Journal of the American Medical Informatics Association | July 24, 2020 | Volume: 28 | Issue: 1 | Pages: 184-189

10.1093/jamia/ocaa188 | PMID 32722749 Get It

AbstractThe COVID-19 pandemic response in the United States has exposed significant gaps in information systems and processes that prevent timely clinical and public health decision-making. Specifically, the use of informatics to mitigate the spread of SARS-CoV-2, support COVID-19 care delivery, and accelerate knowledge discovery bring to the forefront issues of privacy, surveillance, limits of state powers, and interoperability between public health and clinical information systems. Using a consensus-building process, we critically analyze informatics-related ethical issues in light of the pandemic across 3 themes: (1) public health reporting and data sharing, (2) contact tracing and tracking, and (3) clinical scoring tools for critical care. We provide context and rationale for ethical considerations and recommendations that are actionable during the pandemic and conclude with recommendations calling for longer-term, broader change (beyond the pandemic) for public health organization and policy reform.
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity
Seligson, Nathan D. , Warner, Jeremy L. , Dalton, William S. , Martin, David , Miller, Robert S. , Patt, Debra A. , Kehl, Kenneth L. , Palchuk, Matvey B. , Alterovitz, Gil , Wiley, Laura K. , Shen, Feichen , Wang, Yanshan , Nguyen, Khoa A. , Wong, Anthony, Chen, James L. , Warner, Jeremy L , Miller, Robert S , Wiley, Laura K , Wang, Yanshan , Huang, Ming , Meric‐Bernstam, Funda , Bernstam, Elmer V

Mayo Clinic

Journal of the American Medical Informatics Association | July 24, 2020 | Volume: 27 | Issue: 11 | Pages: 1808-1812

10.1093/jamia/ocaa159 | PMID 32885823 Get It

Abstract Defining patient-to-patient similarity is essential for the development of precision medicine in clinical care and research. Conceptually, the identification of similar patient cohorts appears straightforward; however, universally accepted definitions remain elusive. Simultaneously, an explosion of vendors and published algorithms have emerged and all provide varied levels of functionality in identifying patient similarity categories. To provide clarity and a common framework for patient similarity, a workshop at the American Medical Informatics Association 2019 Annual Meeting was convened. This workshop included invited discussants from academics, the biotechnology industry, the FDA, and private practice oncology groups. Drawing from a broad range of backgrounds, workshop participants were able to coalesce around 4 major patient similarity classes: (1) feature, (2) outcome, (3) exposure, and (4) mixed-class. This perspective expands into these 4 subtypes more critically and offers the medical informatics community a means of communicating their work on this important topic.
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
Yee, Douglas , Symmans, W. Fraser , Albain, Kathy S. , Chen, Yunn-Yi, Krings, Gregor , Wei, Shi , Harada, Shuko , Datnow, Brian, Fadare, Oluwole , Klein, Molly, Chen, Beiyun, Adamson, Kathi, Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Magliocco, Anthony M., Feldman, Mike, Rendi, Mara H. , Sattar, Husain, Zeck, Jay , Ocal, Idris Tolgay, Tawfik, Ossama , LeBeau, Lauren, Sahoo, Sunati , Vinh, Tuyethoa N., Chien, A. Jo , Forero‐Torres, Andres , Stringer-Reasor, Erica , Ellis, Erin D. , Lu, Janice , Lang, Julie E. , Clark, Amy S. , Nanda, Rita , Northfelt, Donald W. , Khan, Qamar J. , Viscusi, Rebecca K., Euhus, David , Edmiston, Kirsten K., Kemmer, Kathleen, Park, John W., Liu, Minetta C. , Olopade, Olufunmilayo I. , Leyland‐Jones, Brian , Tripathy, Debasish , Moulder, Stacy L. , Schwab, Richard B. , Lo, Shelly S. , Beckwith, Heather , Haugen, Patricia, Veer, Laura J. van’t , Perlmutter, Jane , Melisko, Michelle , Wilson, Amy , Peterson, Garry , Buxton, Meredith , Paoloni, Melissa, Clennell, Julia L. , Hirst, Gillian L. , Singhrao, Ruby , Steeg, Katherine, Matthews, Jeffrey B. , Asare, Smita , Sanil, Ashish, Esserman, Laura J. , Berry, Donald A. , Tripathy, Debu , Ocal, Idris T, Olopade, Olufunmilayo I , Symmans, W Fraser , Esserman, Laura J , Hirst, Gillian L , Yee, Douglas , DeMichele, Angela , Yau, Christina , Isaacs, Claudine , Chen, Yunn‐Yi , Krings, Gregor, Pambuccian, Stefan E. , Wallace, Anne M. , Pusztai, Lajos , Boughey, Judy C. , Elias, Anthony , Han, Hyo S , Chui, Stephen Y., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Asare, Adam L. , Matthews, Jeffrey B., Berry, Scott

Mayo Clinic

JAMA Oncology | July 23, 2020 | Volume: 6 | Issue: 9 | Pages: 1355

10.1001/jamaoncol.2020.2535 | PMID 32701140 Get It

Intercalary Allograft Reconstruction of the Proximal Tibia With and Without a Free Fibula Flap in Pediatric Patients
Misaghi, Amirhossein , Jackson, Taylor J. , Stans, Anthony A. , Shaughnessy, William J. , Rose, Peter S. , Moran, Steven L. , Houdek, Matthew T.

Mayo Clinic

Journal of Pediatric Orthopaedics | July 23, 2020 | Volume: 40 | Issue: 9 | Pages: e833-e838

10.1097/bpo.0000000000001640 | PMID 32701658 Get It

Background: Limb salvage of the proximal tibia can be difficult due to the growth potential of and functional demands of the pediatric patients. Multiple reconstruction techniques exist, however, the ideal form of reconstruction is yet to be elucidated. The purpose of the current study is to evaluate outcomes in patients with an intercalary resection of the proximal tibia reconstructed with an allograft with or without a free vascularized fibula flap (FVF). Methods: Seventeen pediatric patients (9 males, 8 females) underwent lower extremity limb salvage with the use of intercalary cadaveric allograft at a mean age of 12±4 years. The most common diagnoses were osteosarcoma (n=6) and Ewing sarcoma (n=6). Patients were reconstructed with an allograft alone (n=6) or supplemented with an FVF (n=11). Results: All surviving patients had at least 2 years of clinical follow-up, with the mean follow-up of 12±7 years. The mean time to union of the allograft was 11±4 months, with 6 patients requiring additional bone grafting. There was no difference in the need for an additional bone graft (odds ratio=1.14, P=1.0) between patients with an FVF and those without. Four patients underwent an amputation, all with an allograft alone, due to disease recurrence (n=2) and due to infection (n=2). As such, there was a higher 10-year overall limb-salvage rate when the allograft was combined with an FVF compared with an allograft alone (100% vs. 33%, P=0.001). At last follow-up, the mean Mankin and Musculoskeletal Tumor Society rating was 86%, with a higher mean score in patients reconstructed with an FVF (94% vs. 70%, P=0.002). Conclusion: Use of an intercalary allograft supplemented with an FVF to reconstruct the proximal tibia provides a durable means of reconstruction with an excellent functional outcome following oncologic proximal tibia resection in a pediatric population. Level of Evidence: Level III—therapeutic level.